Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Glioblastoma 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Pheochromocytoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Metastatic Non-hematologic Malignancies 1Melanoma 1Kidney Neoplasms 1Insulinoma 1Glucagonoma 1Gliosarcoma 1Glioma 1Gastrinoma 1Fallopian Tube Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × vatalanib × Clear all
NCT00611793 2009-01-23

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

SCRI Development Innovations, LLC

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡